Navigation Links
Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Date:11/16/2011

eptable bioavailability profile;
  • Cenderitide's PK profile achieved steady-state when delivered through subcutaneous infusion;
  • Weight-based dosing reduced PK variability, as compared to a fixed dosing regimen.

  • "We believe the data from this trial proves that dosing cenderitide with subcutaneous pump technology is a viable strategy for dosing heart failure patients in the out-patient setting," said Hsiao Lieu, MD, Vice President of Clinical Research at Nile. "We now believe that we understand the target dose range for continuous subcutaneous delivery of cenderitide to heart failure patients.  In the next clinical trial, a Phase 2 trial, we hope to test our hypothesis that cenderitide can help reduce hospital re-admission in the post-acute period following ADHF."

    "When dosed continuously in the out-patient setting during the post-acute period, we believe cenderitide has the potential to reduce the re-hospitalization rate following ADHF," said Richard Brewer, Executive Chairman Nile. "If effective, cenderitide may be able to fundamentally change the treatment paradigm of ADHF, potentially reducing the overall financial burden of heart failure on the system."

    About Heart Failure
    Heart failure is the fastest-growing clinical cardiac disease in the U.S. according to the American Heart Association, affecting over 5 million Americans. Over 1 million patients in the U.S. each year are hospitalized with ADHF, an acute exacerbation of heart failure. ADHF is the is the most frequent cause of hospital admission in the U.S. for patients older than 65 years, generating annual inpatient costs of more than $35 billion. Within 90 days following admission for ADHF, approximately 40% of patients return to the hospital. Nile believes that a decrease in the ADHF re-hospitalization rate, which is the clinical target of the cenderitide development program, could both improve the quality of life for patients and decrease the ann
    '/>"/>

    SOURCE Nile Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    3. Orexigen® Therapeutics Reports Third Quarter Financial Results
    4. Silence Therapeutics Provides Corporate and Development Update
    5. Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
    6. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
    7. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
    8. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
    9. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
    10. Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
    11. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/6/2015)... BioSpecifics Technologies Corp. (NASDAQ: BSTC ... products marketed as XIAFLEX ® (collagenase clostridium histolyticum ... the EU, announced today that it will host a ... ET on Friday, March 13, 2015 to report its ... provide a corporate update. In order ...
    (Date:3/6/2015)... BOTHELL, Wash. , March 6, 2015   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... announced that the Company,s fourth quarter and full year 2014 financial ... and that the Company will host a conference call ...
    (Date:3/5/2015)... , March 5, 2015   HX360 ... semi-finalists in the HX360 Innovation Challenge competition. ... will compete to be chosen as one of four ... of senior health system executives and venture capitalists during ... Innovation Challenge takes place at the 2015 HIMSS Annual ...
    (Date:3/5/2015)... (PRWEB) March 05, 2015 Bi-Biomics ... Histology’s paraffin and stain additive. The improvement in ... the binary features present in all daughter cells. ... protocol, chromatin packaging was analyzed at 1000-1600x using ... that chromatin patterning in all daughter cells displayed ...
    Breaking Biology Technology:BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2014 Financial Results on Friday, March 13, 2015 2BioLife Solutions to Report Fourth Quarter and Full Year 2014 Financial Results and Provide Business Update on March 12, 2015 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 3HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 4
    ... Event Underscores Commitment to Diverse Workforce, OAKLAND, ... diversity in the workplace, Kaiser Permanente today opened,its ... This year,s conference will focus on Kaiser ... integrate diversity into every,aspect of daily business operations. ...
    ... RICHMOND, Va., Dec. 12 Insmed Inc. (Nasdaq:,INSM), ... grant of $2,087,325 from,the Muscular Dystrophy Association (MDA). ... of the external costs associated with Insmed,s 24-week,Phase ... Dystrophy (MMD)., Insmed, a development stage biopharmaceutical ...
    ... An IND has Been Filed With the FDA for ... Developed Under the Company,s Collaboration with Roche., ... today that an Investigational New Drug application (IND) for ... has,been filed with the FDA by Roche. Genentech and ...
    Cached Biology Technology:Kaiser Permanente to Host 30th Annual Diversity Conference 2Kaiser Permanente to Host 30th Annual Diversity Conference 3Insmed Awarded $2.1 Million by Muscular Dystrophy Association 2Insmed Awarded $2.1 Million by Muscular Dystrophy Association 3Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 2Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 3
    (Date:2/5/2015)... DUBLIN , Jan. 28, 2015 Research ... announced the addition of the "Global Biometrics ... Use, Regions and Countries " report to their ... market, Asia-Pacific is anticipated ... by 2015, owing to increasing government spending towards ...
    (Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: ... market in general the State of Washington,s ... for a new enrollment and central issuance system for driver,s ... The project planning and development will start in ...
    (Date:1/22/2015)... , Jan. 15, 2015  BellBrook Labs, a leader ... announced the launch of a TR-FRET (time resolved ... Transcreener UDP Assay, a high throughput screening assay ... assay will allow for sensitive detection of hundreds ...
    Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
    ... SCM Microsystems, a business unit of Identive Group, Inc. (Nasdaq: ... secure identity and secure exchange, announced that more than 700,000 of its ... new electronic identification program managed by Germany ,s Federal Ministry of ... , , ...
    ... real-world evidence supporting the idea that hand washing can ... a new study showing a connection between fecal bacteria ... and health in households in a developing country in ... & Technology , a semi-monthly journal. Alexandria ...
    ... AUGUSTA, GA. More electrodes and a thinner, more ... improve conventional cochlear implants, a team of Medical College ... Candidates for cochlear implantsan estimated million in the ... in both ears. An implant does not restore normal ...
    Cached Biology News:SCM Microsystems to Supply Readers for German Electronic ID Program 2SCM Microsystems to Supply Readers for German Electronic ID Program 3New cochlear implant could improve outcomes for patients 2
    ... Guinea Pig Serum • Guinea Pig serum ... Available Anticoagulants: N-02: Citrate ... N-08: Potassium Oxalate N-10: ... ACD N-07: CPD N-09: ...
    EPH electrode, anode, 1. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
    LIVE/DEAD® Cell-Mediated Cytotoxicity Kit *for animal cells* *2000 assays*...
    Human Xg Affinity Purified Polyclonal Ab Keywords: Xg glycoprotein, hereditary hemorrhagic telangiectasia Protein Family: ...
    Biology Products: